Vaccination Schedule After Relocation

Core Principles

The American Academy of Pediatrics recommends that vaccination series interrupted by relocation should be continued at the next clinic visit without repeating doses, and using the same manufacturer's product throughout is preferred when feasible 1, 2
Any valid dose of DTaP-containing combination vaccine counts toward completion of the series, regardless of where it was administered 2

The Centers for Disease Control and Prevention recommends that the second dose of the DTaP/IPV/Hib/Hepatitis B combination vaccine series should be given at approximately 2 months of age, with a minimum interval of 4 weeks between doses 2, 3
The third dose of the DTaP/IPV/Hib/Hepatitis B combination vaccine series should be given at 6 months of age, with a minimum 4-week interval from the second dose 1, 2
The fourth dose (booster) of the DTaP/IPV/Hib/Hepatitis B combination vaccine series should be given at 15-18 months of age, with a minimum 6 months after the third dose 2, 4
The final DTaP dose should be given at 4-6 years of age 1, 2

The American Academy of Pediatrics recommends that the second dose of Hepatitis B vaccine should be given at 1-2 months of age, and the third dose must be administered at ≥24 weeks of age with at least 8 weeks after the second dose 1, 5
The Centers for Disease Control and Prevention recommends that if using PRP-OMP conjugate (PedvaxHIB), only 2 primary doses are needed at 2 and 4 months, followed by a booster at 12-15 months 6
If using HbOC or PRP-T conjugates, 3 primary doses are needed (2, 4, 6 months) plus booster at 12-15 months 6, 7

The Centers for Disease Control and Prevention recommends that different brands of DTaP-containing combination vaccines can be used interchangeably to complete the series, and vaccination should not be delayed if the original brand is unavailable 1, 2

The American Academy of Pediatrics recommends obtaining complete vaccination records to verify the exact vaccine product and date of first dose 1
Local reactions (pain, redness, swelling) increase with subsequent doses, particularly after the 4th and 5th doses, primarily due to the pertussis component, and should be monitored 8